An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164.

Trial Profile

An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2012

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Dec 2011 Actual patient number is 21 according to ClinicalTrials.gov.
    • 16 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 16 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top